Abstract:

Objective To investigate the efficacy and toxicity of raltitrexed as second-line chemotherapy for advanced colorectal cancer in elderly patients，and to discuss the correlation between clinical features and survival. Methods We retrospectively analyzed elderly advanced colorectal cancer patients who were treated with raltitrexed as second-line chemotherapy in Ruikang Affiliated Hospital of Guangxi Traditional Medical University from 1st January 2012 to 31st December 2016. Results A total of 27 patients was included. The response rate was 3.7%，the disease control rate was 48.15%，the median progression free survival was 3.8 months，the median overall survival was 10 months. The main adverse reactions included granulopenia，anemia，transaminase elevation，nausea/vomiting and exhausted，most of which were grade Ⅰ-Ⅱ. Multiple factor analysis showed PS status and liver metastasis were the main independent predictors on overall survival． Conclusion Raltitrexed as the second line chemotherapy showed satisfactory efficacy and safety to treat the elderly patients with advanced colorectal cancer.

Key words: Colorectal neoplasms, Advanced stage, Elder, Raltitrexed , Efficacy